Four insights:
1. The company signed a private label agreement with a biologics company to enter the cellular bone graft market.
2. Camber Spine’s allogenic bone matrix product, Scylla, consists of spine-derived cells to support the osteogenic healing process.
3. Scylla features an osteoconductive 3D scaffold with cortical and cancellous properties and demineralized bone scaffold with osteoinductive potential.
4. Zion Market Research reported the global bone grafts and substitutes market to be a $2.7 billion industry, predicted to grow to $4.2 billion by 2026.
More articles on biologics:
Dr. Robert Brady: Robotics in spinal fusion and how the trend will develop in spine
Orthofix names DePuy, Medtronic, Biomet veteran the next CEO
Medicrea receives FDA approval for new screw device
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.